Keywords: آنتاگونیست آندروژنی; Androgen antagonists; Cardiovascular diseases; Radiotherapy; Prostatectomy; Comparative effectiveness research; Brachytherapy;
مقالات ISI آنتاگونیست آندروژنی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آنتاگونیست آندروژنی; androgen antagonists; dementia; prostatic neoplasms; Alzheimer disease; cognition; ADT; androgen deprivation therapy; ICCTF; International Cognition and Cancer Task Force;
Keywords: آنتاگونیست آندروژنی; prostatic neoplasms; prostate-specific antigen; brachytherapy; androgen antagonists; disease-free survival; ADT; androgen deprivation therapy; bDFS; biochemical disease-free survival; BF; biochemical failure; EBRT; external beam radiotherapy; LDR-BT; low
Keywords: آنتاگونیست آندروژنی; prostatic neoplasms; androgen antagonists; non-alcoholic fatty liver disease; Medicare; SEER program; ADT; androgen deprivation therapy; AJCC; American Joint Committee on Cancer; NAFLD; nonalcoholic fatty liver disease; NASH; nonalcoholic steatohepatitis;
Keywords: آنتاگونیست آندروژنی; Androgen antagonists; Neoplasm metastasis; Nomograms; Patient-reported outcome measures; Prostatic neoplasms;
Keywords: آنتاگونیست آندروژنی; prostatic neoplasms; androgen antagonists; antineoplastic agents; hormonal; drug related side effects and adverse reactions; risk; ADT; androgen deprivation therapy; AMI; acute myocardial infarction; CADT; continuous ADT; GnRH; gonadotropin-releasing horm
Keywords: آنتاگونیست آندروژنی; prostatic neoplasms; prostate-specific antigen; androgen antagonists; delayed-action preparations; calcium sulfate; 2D; 2-dimensional; 2-HOF; 2-hydroxyflutamide; ADC; apparent diffusion coefficient; Cho; choline; Cit; citrate; Cr; creatine; DWI; diffusion
Keywords: آنتاگونیست آندروژنی; Prostatic neoplasms; Radiotherapy; Androgen antagonists; Clinical trial; Review;
Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor
Keywords: آنتاگونیست آندروژنی; bladder neoplasms; neoplasm recurrence; local; androgen antagonists; prevention and control; 5-alpha reductase inhibitors; ADT; androgen deprivation therapy; AR; androgen receptor; AST; androgen suppression therapy; BCG; bacillus Calmette-Guérin; BPH; be
Castration-Resistant Prostate Cancer: AUA Guideline
Keywords: آنتاگونیست آندروژنی; prostatic neoplasms; androgen antagonists; drug therapy; immunotherapyADT, androgen deprivation therapy; CRPC, castration-resistant prostate cancer; FDA, Food and Drug Administration; H&P, history and physical; mCRPC, metastatic castration-resistant prost
Changes in Initial Treatment for Prostate Cancer Among Medicare Beneficiaries, 1999-2007
Keywords: آنتاگونیست آندروژنی; Prostatic neoplasms; Prostatectomy; Intensity-modulated radiotherapy; Androgen antagonists; Medicare; Physicians' practice patterns;
Impact of Androgen Deprivation Therapy on Weight Gain Differs by Age in Men with Nonmetastatic Prostate Cancer
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; androgen antagonists; weight gain; aged; ADT; androgen deprivation therapy; BMI; body mass index; PC; prostate cancer;
Impact métabolique de la suppression androgénique dans le cancer de la prostate
Keywords: آنتاگونیست آندروژنی; Prostate; Néoplasies prostatiques; Antagonistes; Agonistes; Castration; Diabète de type 2; Syndrome métabolique; Dyslipidémie; ObésitéProstate; Prostatic neoplasms; Androgen antagonists; Castration; Diabetes mellitus type 2; Metabolic syndrome X; Dyslipid
Androgen Deprivation Therapy for Prostate Cancer Prevention: What Impact Do Related Adverse Events Have on Quality of Life?
Keywords: آنتاگونیست آندروژنی; Androgen antagonists; Gynecomastia; Primary prevention; Sexual dysfunction; Utilities
The Effects of LongâTerm Androgen Deprivation Therapy on Penile Length in Patients with Prostate Cancer: A SingleâCenter, Prospective, OpenâLabel, Observational Study
Keywords: آنتاگونیست آندروژنی; Prostate Carcinoma; Androgen Antagonists; Body Measures; Penis; Penile Length;
Acute Versus Chronic Exposure to Androgen Suppression for Prostate Cancer: Impact on the Exercise Response
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; androgen antagonists; resistance training; body composition; ASM; appendicular skeletal muscle; AST; androgen suppression therapy; CRP; C-reactive protein; PSA; prostate specific antigen; RCT; randomized, controlled trial; R
Does Hormone Therapy Exacerbate the Adverse Effects of Radiotherapy in Men With Prostate Cancer? A Quality of Life Study
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; quality of life; radiotherapy; androgen antagonists; ADT; androgen deprivation therapy; AUASI; American Urological Association symptom index; BT; brachytherapy; EBRT; external beam RT; HRQOL; health related quality of life;
Impact of Hormonal Therapy on Intermediate Risk Prostate Cancer Treated With Combination Brachytherapy and External Beam Irradiation
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; brachytherapy; radiotherapy; androgen antagonists; AST; androgen suppressive therapy; BED; biologically effective dose; D90; dose delivered to hottest 90% of prostate; EBRT; external beam irradiation; FFBF; freedom from bioc
Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men
Keywords: آنتاگونیست آندروژنی; prostate; androgen antagonists; fracture; osteoporosis; iatrogenic diseaseADT, androgen deprivation therapy; BMD, bone mineral density; LHRH, luteinizing hormone-releasing hormone; OCR, Ontario Cancer Registry
Expression of Estrogen Related Proteins in Hormone Refractory Prostate Cancer: Association With Tumor Progression
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; androgen antagonists; estrogens; gene expression5AR, 5α-reductase; ADT, androgen deprivation therapy; AR, androgen receptor; BCAR1, breast cancer anti-estrogen resistance 1; ERA, estrogen receptor α; ERB, estrogen receptor β
A large proportion of patients with prostate cancer undergoing androgen deprivation therapy continue to die from non-cancer causes in the PSA era
Keywords: آنتاگونیست آندروژنی; ADT; androgen deprivation therapy; LHRH; luteinizing hormone-releasing hormone; MRC; Medical Research Council; PCa; prostate cancer; PSA; prostate specific antigen; VACURG; Veterans Administration Cooperative Urological Research Group; Androgen antagonist
Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation Therapy
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; androgen antagonists; zoledronic acid; osteoporosisADT, androgen deprivation therapy; BMD, bone mineral density; BMI, body mass index; CaP, prostate cancer; COPD, chronic obstructive pulmonary disorder; DXA, dual energy x-ra
Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; androgen antagonists; testosterone; gonadotropin-releasing hormoneADT, androgen deprivation therapy; DES, diethylstilbestrol; DHT, dihydroxytestosterone; GnRH-A, gonadotropin-releasing hormone agonist; LHRH, luteinizing horm
Alternative Nonsteroidal Antiandrogen Therapy for Advanced Prostate Cancer That Relapsed After Initial Maximum Androgen Blockade
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; neoplasm recurrence; local; androgen antagonists; JapanAR, androgen receptor; AWS, antiandrogen withdrawal syndrome; BCL, bicalutamide; CAB, combined androgen blockade; CMA, chlormadinone acetate; CPA, cyproterone acetate; C
Managing Bone Loss in Men With Locally Advanced Prostate Cancer Receiving Androgen Deprivation Therapy
Keywords: آنتاگونیست آندروژنی; prostate; bone and bones; prostatic neoplasms; androgen antagonists; osteoporosisADT, androgen deprivation therapy; AE, adverse effect; BMD, bone mineral density; BMI, body mass index; BSAP, bone-specific alkaline phosphatase; DES, diethylstilbestrol; DEX
The Effect of Androgen Deprivation Therapy on Periodontal Disease in Men With Prostate Cancer
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; osteoporosis; periodontal diseases; androgen antagonists; ADT; androgen deprivation therapy; BMD; bone mineral density;
Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy
Keywords: آنتاگونیست آندروژنی; testosterone; prostatic neoplasms; androgen antagonists; castrationADT, androgen deprivation therapy; AIP, androgen independent progression; LH-RH, luteinizing hormone releasing hormone; mAb, maximal androgen blockade; PCa, prostate cancer; PSA, prostate
Predictors of Overall and Cancer-Free Survival of Patients With Localized Prostate Cancer Treated With Primary Androgen Suppression Therapy: Results From the Prostate Cancer Outcomes Study
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; androgen antagonists; mortality; nomogramsAST, androgen suppression therapy; DRE, digital rectal examination; PAST, primary AST; PCOS, Prostate Cancer Outcomes Study; PSA, prostate specific antigen
Bone Health in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; bone and bones; androgen antagonists; osteoporosisADT, androgen deprivation therapy; BMD, bone mineral density; DXA, dual x-ray absorptiometry; GI, gastrointestinal; GnRH, gonadotropin-releasing hormone; RANKL, receptor acti
Bone Related Events in High Risk Prostate Cancer
Keywords: آنتاگونیست آندروژنی; prostate; bone and bones; prostatic neoplasms; androgen antagonists; osteoporosisADT, androgen deprivation therapy; BMD, bone mineral density; DXA, dual energy x-ray absorptiometry; LHRH, luteinizing hormone-releasing hormone; NTx, N-telopeptide of type 1
The Effect of Androgen Deprivation Therapy on Fasting Serum Lipid and Glucose Parameters
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; androgen antagonists; glucose; lipids; A; abarelix; ADT; androgen deprivation therapy; B; bicalutamide; GnRH; gonadotropin releasing hormone; HbA1C; hemoglobin A1C; HDL; high density lipid; HDL-C; HDL lipoprotein; LA; leupro
The Bicalutamide 150 Mg Early Prostate Cancer Program: Findings of the North American Trial at 7.7-Year Median Followup
Keywords: آنتاگونیست آندروژنی; prostate; androgen antagonists; prostatic neoplasms; clinical trials; bicalutamideEPC, early prostate cancer; NQ, not quantifiable (below 0.2 ng/ml limit of quantification); OS, overall survival; PFS, progression-free survival; PSA, prostate specific anti
The Case for Secondary Hormonal Therapies in the Chemotherapy Age
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; androgen antagonists; ketoconazole; adrenal cortex hormonesAAWD, antiandrogen withdrawal; ADT, androgen deprivation therapy; AIPC, androgen independent prostate cancer; AL, alendronate; AR, androgen receptor; CAB, combined a
ANDROGEN DEPRIVATION USE WITH EXTERNAL BEAM RADIATION FOR PROSTATE CANCER: RESULTS FROM CaPSURE™
Keywords: آنتاگونیست آندروژنی; prostate; prostatic neoplasms; androgen antagonists; radiotherapy; combined modality therapy
Bicalutamide ('Casodex') 150Â mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme
Keywords: آنتاگونیست آندروژنی; Androgen antagonists; Prostate cancer; Radiotherapy; Bicalutamide; Adjuvant therapy;